Current, new and future treatments of osteoporosis

Rheumatology International

Volumn 31, Issue 3, 2011, Pages 289-300

  Salari Sharif, Pooneh ^a   Abdollahi, Mohammad ^b   Larijani, Bagher ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone formation; Bone resorption; New therapies; Osteoporosis

Indexed keywords

ADRENOMODULIN; ALENDRONIC ACID; AMYLIN; ARZOXIFENE; BALICATIB; BAZEDOXIFENE; CALCITONIN; CALCIUM; CARNITINE; CYSTEINE PROTEINASE INHIBITOR; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GESTAGEN; HORMONE; ISOVALERYL L CARNITINE; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; ODANACATIB; OSPEMIFENE; PARATHYROID HORMONE[1-34]; RALOXIFENE; REVEROMYCIN A; SCLEROSTIN ANTIBODY; SOMATOMEDIN; STRONTIUM RANELATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITRONECTIN RECEPTOR ANTAGONIST; ZOLEDRONIC ACID;

ACUTE PHASE REACTION; ALLERGIC REACTION; ARTHRALGIA; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE STRENGTH; BREAST CANCER; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; ENDOMETRIUM THICKNESS; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; LEG CRAMP; MEDLINE; MENOPAUSAL SYNDROME; MESENCHYMAL STEM CELL; MORPHEA; MYALGIA; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; POLYP; POSTMENOPAUSAL VASOMOTOR SYMPTOM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; VAGINA ATROPHY; VAGINA BLEEDING; VERTEBRA FRACTURE;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 79954441929     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-010-1586-z     Document Type: Review

References (153)

1. MS Nanes CB Kallen 2009 Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis Fertil Steril 92 2 403 412 1:CAS:528:DC%2BD1MXht1Gntb7P 19559412
2. P Salari A Rezaie B Larijani M Abdollahi 2008 A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis Med Sci Monit 14 3 RA37 RA44 1:CAS:528:DC%2BD1cXks1Wisr4%3D 18301367
3. JC Gallagher AJ Sai 2010 Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis Maturitas 65 301 307 1:CAS:528:DC%2BC3cXjtVCksro%3D 20116187
4. M Abdollahi B Larijani R Rahimi P Salari 2005 Role of oxidative stress in osteoporosis Therapy 2 5 787 796 1:CAS:528:DC%2BD2MXhtFChtLvK (Pubitemid 41447768)
5. G Yousefzadeh B Larijani A Mohammadirad, et al. 2006 Determination of oxidative stress status and concentration of TGF-β1 in the blood and saliva of osteoporotic subjects Ann New York Acad Sci 1091 142 150 1:CAS:528:DC%2BD2sXjsFShu7s%3D (Pubitemid 47092232)
6. Salari P, Asalforoush M, Ameri F, Larijani B, Abdollahi M (2010) The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age 32(2):179-186
7. P Salari M Abdollahi 2009 Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review Inflamm Allergy Drug Targets 8 3 169 175 1:CAS:528:DC%2BD1MXoslCju74%3D 19601876
8. P Salari M Abdollahi 2008 Association of hyperhomocysteinemia with osteoporosis: a systematic review Therapy 5 2 215 222 (Pubitemid 351513513)
9. HA Bischoff-Ferrari JR Rees MV Grau E Barry J Gui JA Baron 2008 Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial Am J Clin Nutr 87 1945 1951 1:CAS:528:DC%2BD1cXnslWqu7k%3D 18541589 (Pubitemid 351872663)
10. RD Jackson AZ LaCroix M Gass, et al. 2006 Calcium plus vitamin D supplementation and the risk of fractures N Eng J Med 354 669 683 1:CAS:528:DC%2BD28XhsVWksr0%3D (Pubitemid 43247138)
11. J Porthouse S Cockayne C King, et al. 2005 Randomised controlled trial of calcium, supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care BMJ 330 1003 1:CAS:528:DC%2BD2MXkslKlu78%3D 15860827
12. B Dawson-Hughes GE Dallal EA Krall L Sadwski N Sahyoun S Tannenbaum 1990 A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women N Eng J Med 323 878 883 1:STN:280:DyaK3czntVSmtQ%3D%3D (Pubitemid 20341558)
13. BM Tang GD Eslick C Nowson C Smith A Bensoussan 2007 use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 370 657 666 1:CAS:528:DC%2BD2sXpsFWrsbc%3D 17720017 (Pubitemid 47285316)
14. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10527181 (Pubitemid 29483192)
15. HG Bone D Hosking JP Devogelaer, et al. 2004 Ten years experience with alendronate for osteoporosis in postmenopausal women N Eng J Med 350 1189 1199 1:CAS:528:DC%2BD2cXit12rsLc%3D (Pubitemid 38339363)
16. G Wells A Cranney J Peterson, et al. 2008 Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 CD004523 18254053
17. B Borah TE Dufresne PA Chmielewski, et al. 2004 Risedronate preserves bone architecture in ostmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography Bone 34 736 746 1:CAS:528: DC%2BD2cXisF2ntbo%3D 15050906 (Pubitemid 38393811)
18. DM Black AV Schwartz KE Ensrud, et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938 1:CAS:528:DC%2BD2sXnvVGh 17190893 (Pubitemid 46021497)
19. AV Schwartz DC Bauer JA Cauley, et al. 2007 Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX Trial J Bone Miner Res 22 Suppl 1 S1057
20. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 1:CAS:528: DC%2BD3sXkslOhsb0%3D 12817758 (Pubitemid 37294942)
21. CH Chenut III A Skag C Christiansen, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 (Pubitemid 41094364)
22. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 1:CAS:528:DC%2BD2sXntVOlsrY%3D 17308956 (Pubitemid 47019996)
23. MP Whyte D Wenkert KL Clements WH McAlister S Mumm 2003 Bisphosphonate-induced osteoporosis N Eng J Med 349 457 463 1:CAS:528: DC%2BD3sXms1Ogsrc%3D
24. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Eng J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
25. KW Lyles CS Colon-Emeric JS Magaziner, et al. 2007 HORIZON recurrent fracture trial: zoledronic acid in reducing clinical fracture and mortality after hip fracture N Eng J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN (Pubitemid 350044800)
26. Zoledronic acid prescribing information. Available at http://www.pharma.us.novartis.com/products/pi/pdf/reclast.pdf
27. S Ljunghall P Gärdsell O Johnell, et al. 1991 Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study Calcif Tissue Int 49 17 19 1:STN:280:DyaK3MzntFWrsg%3D%3D 1893291
28. G Thamsborg TL Storm R Sykulski E Brinch HK Nielsen OH Sorensen 1991 Effect of different doses of nasal calcitonin on bone mass Calcif Tissue Int 48 302 307 1:CAS:528:DyaK3MXlvF2itrY%3D 2054714
29. NM Nielsen P von der Recke MA Hansen K Overgaard C Christiansen 1994 Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers Calcif Tissue Int 55 8 11 1:STN:280: DyaK2M%2FgslWmsA%3D%3D 7922794 (Pubitemid 24192830)
30. SL Silverman C Chesnut K Andriano, et al. 1998 Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF Study J Bone Miner Res 23 Suppl 5 S174
31. BM Misof P Roschger F Cosman, et al. 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 1150 1156 1:CAS:528:DC%2BD3sXit1egu7k%3D 12629098 (Pubitemid 36337769)
32. JY Reginster AN Taquet G Fraikin C Gosset B Zegels 1997 Parathyroid hormone in the treatment of involutional osteoporosis: back to the future Osteoporos Int 7 Suppl 3 S163 S168 9536325
33. RM Neer CD Arnaud JR Zanchetta, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis New Eng J Med 344 1434 1441 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808 (Pubitemid 32402100)
34. JJ Body GA Gaich WH Scheele, et al. 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 4528 4535 1:CAS:528:DC%2BD38XnvFCrsr8%3D 12364430 (Pubitemid 35247036)
35. AB Hodson DC Bauer DW Dempster, et al. 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 688 703 (Pubitemid 41127277)
36. SL Greenspan HG Bone MP Ettinger, et al. 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis Ann Intern Med 146 326 339 17339618 (Pubitemid 351650593)
37. DM Antoniucci DE Sellmeyer JP Bilezikian, et al. 2007 Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis J Clin Endocrinol Metab 92 942 947 1:CAS:528:DC%2BD2sXjtlGnu7k%3D 17164314 (Pubitemid 46465667)
38. JE Rossouw GL Anderson RL Prentice, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized Controlled Trial JAMA 288 321 333 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397 (Pubitemid 34761611)
39. M Kleerekoper 2006 Osteoporosis prevention and therapy: preserving and building strength through bone quality Osteoporos Int 17 1707 1715 1:STN:280:DC%2BD28nitVSltQ%3D%3D 16909196 (Pubitemid 44607390)
40. N Harada T Utsumi Y Takagi 1993 Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis Proc Natl Acad Sci USA 90 11312 11316 1:CAS:528:DyaK2cXitFegtL8%3D 8248245 (Pubitemid 23354419)
41. BL Riggs LJ Melton III 2002 Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density J Bone Miner Res 17 11 14 11771656 (Pubitemid 33150991)
42. S Sarkar BH Mitlak M Wong DM Black KD Harper 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1 10 1:CAS:528:DC%2BD38XktFyisg%3D%3D 11771654 (Pubitemid 33150990)
43. PD Delmas KE Ensrud JD Adachi, et al. 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 3609 3617 1:CAS:528:DC%2BD38XmtF2gsLg%3D 12161484 (Pubitemid 34879503)
44. E Barrett-Connor L Mosca P Collins, et al. 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Eng J Med 355 125 137 1:CAS:528:DC%2BD28Xmsl2ktrs%3D (Pubitemid 44050394)
45. S Martino JA Cauley E Barrett-Connor, et al. 2004 Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 1751 1761 1:CAS:528:DC%2BD2cXhtVCrsrjM 15572757 (Pubitemid 39654569)
46. S Epstein 2006 Update of current therapeutic options for the treatment of postmenopausal osteoporosis Clin Therapeut 28 151 173 1:CAS:528: DC%2BD28Xmtl2lsbk%3D
47. M Hirata M Inada C Matsumoto, et al. 2009 A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone Biochem Biophys Res Commun 380 218 222 1:CAS:528:DC%2BD1MXitlWqtLk%3D 19159615
48. ChristiansenC Silverman HK Genant, et al. 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 1:CAS:528:DC%2BD1MXosVylsbo%3D 18665787
49. SR Cummings R Eastell K Ensrud, et al. 2008 The effects of lasofoxifene on fractures, breast cancer: 3-year results from the PEARL trial J Bone Miner Res 1288 S81
50. S Ronkin L Clarke P Boudes, et al. 2001 TSE-424, a novel tissue selective estrogen, reduce biochemical indices of bone metabolism in a dose related fashion J Bone Miner Res 16 S1 S413
51. X Ling L Jianli L Jingfang, et al. 2003 Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on biochemical markers of bone metabolism in a Chinese population Osteoporos Int 14 S97 S98
52. PD Miller AA Chines C Christiansen, et al. 2008 Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo, and active-controlled study J Bone Miner Res 23 525 535 1:CAS:528:DC%2BD1cXltFyhsb8%3D 18072873 (Pubitemid 351501893)
53. JV Pinkerton DF Archer WH Utian, et al. 2009 Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 6 1102 1108 19546825
54. SY Smith D Minck J Jolette, et al. 2005 Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkey J Bone Miner Res 20 S1 S174
55. HZ Ke GL Foley HA Simmons V Shen DD Thompson 2004 Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats Endocrinology 145 1996 2005 1:CAS:528:DC%2BD2cXis1Sisbk%3D 14726439 (Pubitemid 38402409)
56. XN Wang HA Simmons CT Salatto PG Cosgrove DD Thompson 2006 Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats Menopause 13 609 620 16837883 (Pubitemid 44079531)
57. MR McClung E Siris S Cummings, et al. 2006 Prevention of bone loss in postmenopausal women treated with lasofoxofene compared with raloxifene Menopause 13 377 386 16735934
58. SR Cummings R Eastell K Ensrud, et al. 2008 The effects of lasofoxifene on fractures, breast cancer: 3-year results from the PEARL Trial J Bone Miner Res 23 81
59. Q Qu H Zheng J Dahllund, et al. 2000 Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology 141 809 820 1:CAS:528:DC%2BD3cXmvFCrug%3D%3D 10650964 (Pubitemid 32250507)
60. J Komi J Heikkinen EM Rutanen K Halonen R Lammintausta O Ylikorkala 2004 Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol 18 152 158 1:CAS:528: DC%2BD2cXnslWku7c%3D 15255284 (Pubitemid 38328094)
61. J Komi KS Lankinen M DeGregorio, et al. 2006 Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab 24 314 318 1:CAS:528:DC%2BD28XmsVShtro%3D 16816926 (Pubitemid 43992675)
62. V Deshmane S Krishnamurthy AS Melemed P Peterson AU Buzdar 2007 Phase III double-blind trial of arzoxifene compared with tamoxifene for locally advanced or metastatic breast cancer J Clin Oncol 25 4967 4973 1:CAS:528: DC%2BD2sXhtlOhtbfK 17971595 (Pubitemid 350220429)
63. M Sato CH Turner T Wang MD Adrian E Rowley HU Bryant 1998 LY353381.HCI: a novel raloxifene analog with improved SERM potency and efficacy in vivo J Pharmacol Exp Ther 287 1 7 1:CAS:528:DyaK1cXmvVSqt7k%3D 9765314 (Pubitemid 29140178)
64. YL Ma HU Bryant Q Zeng, et al. 2002 Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats J Bone Miner Res 17 2256 2264 1:CAS:528:DC%2BD38XpsV2lsbo%3D 12469920 (Pubitemid 35416760)
65. M Stolina PJ Kostenuik WC Dougall LA Fitzpatrick DJ Zack 2007 RANKL inhibition: from mice to men (and women) Adv Exp Med Biol 602 143 150 17966399
66. AE Kearns S Khosla PJ Kostenuik 2007 Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr Rev 29 155 192 18057140
67. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (Pubitemid 28180851)
68. EM Lewiecki PD Miller MR McClung, et al. 2007 Two-year treatment with densumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711 (Pubitemid 351229299)
69. PD Miller MA Bolognese EM Lewieki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 1:CAS:528:DC%2BD1cXosVOitrk%3D 18539106
70. JP Brown RL Prince C Deal, et al. 2009 Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 1:CAS:528:DC%2BD1MXht1yrtbc%3D 18767928
71. S Cummings J Zanchetta M McClung, et al. 2009 The effects of twice-yearly denosumab on fracture risk in women with osteoporosis Osteoporos Int 20 516
72. MR McClung EM Lewiecki SB Cohen MA Bolognese, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Eng J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D (Pubitemid 43290920)
73. S Cummings J San Martin M McClung, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Eng J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF
74. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 4875 4882 1:CAS:528:DC%2BD1cXhtlGitrzO 18725648
75. MR Smith B Egerdie NH Toriz, et al. 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Eng J Med 361 8 745 755 1:CAS:528:DC%2BD1MXhtVWls7rF
76. S O'Donnell A Cranney GA Wells, et al. 2006 Strontium ranelate for preventing and treating postmenopausal osteoporosis Cochrane Database Syst Rev 18 CD005326
77. E Seeman J Devogelaer R Lorenc, et al. 2008 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia J Bone Miner Res 23 433 438 1:CAS:528:DC%2BD1cXjsl2itbo%3D 17997711 (Pubitemid 351304674)
78. GM Blake I Fogelman 2007 The correction of BMD measurements for bone strontium content J Clin Densitometr 10 259 265 (Pubitemid 47198528)
79. E Bonnelye A Chabadel F Saltel, et al. 2008 Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro Bone 42 129 138 1:CAS:528:DC%2BD2sXhsVOrtr3E 17945546 (Pubitemid 350297175)
80. LL Zhu S Zaidi Y Peng, et al. 2007 Induction of a program gene expression during osteoblast differentiation with strontium ranelate Biochem Biophys Res Commun 355 307 311 1:CAS:528:DC%2BD2sXitFOlsrw%3D 17300752 (Pubitemid 46282628)
81. N Chattopadhyay SJ Quinn O Kifor, et al. 2007 The calcium-sensing receptor (CaR) is involved in strontium ranelate induced osteoblast proliferation Biochem Pharmacol 74 438 447 1:CAS:528:DC%2BD2sXntFamurs%3D 17531955 (Pubitemid 46970843)
82. P Ammann I Badoud S Barraud, et al. 2007 Strontium ranelate treatment improves trabecular and cortical intrinsic boe tissue quality, a determinant of bone strength J Bone Miner Res 22 1419 1425 1:CAS:528:DC%2BD2sXhtVynsLjO 17547534 (Pubitemid 351339686)
83. S Choudhary P Halbout C Alander, et al. 2007 Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins J Bone Miner Res 22 1002 1010 1:CAS:528:DC%2BD2sXpt1Knsbg%3D 17371157 (Pubitemid 351339722)
84. O Bruyere C Roux J Detilleux, et al. 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 3076 3081 1:CAS:528: DC%2BD2sXptl2hsb0%3D 17566094 (Pubitemid 47236373)
85. C Roux JY Reginster J Fechtenbaum, et al. 2006 Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536 542 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D 16598373
86. JY Reginster E Seeman MC De Vernejoul, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822 1:CAS:528:DC%2BD2MXkt1Wgt78%3D 15728210 (Pubitemid 40686329)
87. PJ Meunier C Roux E Seeman, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis New Eng J Med 350 459 468 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D 14749454 (Pubitemid 38133766)
88. PJ Meunier DO Slosman PD Delmas, et al. 2002 Strontium ranelate: dosedependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial J Clin Endocrinol Metab 87 2060 2066 1:CAS:528:DC%2BD38XjsFGhtL4%3D 11994341 (Pubitemid 34521489)
89. JY Reginster R Deroisy M Dougados, et al. 2002 Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, doublemasked, dose-ranging, placebo-controlled PREVOS trial Osteoporos Int 13 925 931 1:CAS:528:DC%2BD38XptFGitrc%3D 12459934 (Pubitemid 36050269)
90. E Seeman B Vellas C Benhamou, et al. 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older J Bone Miner Res 21 1113 1120 1:CAS:528:DC%2BD28XntlWqu7k%3D 16813532
91. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Protelos/ PressRelease-Protelos-41745807en.pdf
92. M Shahnazari W Yao M Corr NE Lane 2008 Targeting the Wnt signaling pathway to augment bone formation Curr Osteoporos Rep 6 142 148 19032924
93. AG Robling T Bellido CH Turner 2006 Mechanical stimulation in vivo reduces osteocyte expression of sclerostin J Musculoskelet Neuronal Interact 6 354 1:STN:280:DC%2BD28jkslWktQ%3D%3D 17185821 (Pubitemid 46099713)
94. AG Robling PJ Niziolek LA Baldridge, et al. 2007 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin J Biol Chem 283 5866 5875 18089564
95. MK Sutherland JC Geoghegan C Yu, et al. 2004 Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation Bone 35 828 835 1:CAS:528:DC%2BD2cXnvV2rtLw%3D 15454089 (Pubitemid 39349213)
96. DG Winkler C Yu JC Geoghegan, et al. 2004 Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex J Biol Chem 279 36293 36298 1:CAS:528:DC%2BD2cXmvFCntbw%3D 15199066 (Pubitemid 39128966)
97. O Leupin I Kramer NM Collette, et al. 2007 Control of the SOST bone enhancer by PTH using MEF2 transcription factors J Bone Miner Res 22 1957 1967 1:CAS:528:DC%2BD2sXhsVyjtrnL 17696759 (Pubitemid 351229312)
98. G Silvestrini P Ballanti M Sebastiani, et al. 2008 OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST J Mol Histol 39 237 242 1:CAS:528:DC%2BD1cXjsFWrsLY%3D 18158586 (Pubitemid 351422033)
99. RL Van Bezooijen SE Papapoulos CW Löwik 2005 Bone morphogenetic proteins and their antagonists: the sclerostin paradigm J Endocrinol Invest 28 8 Suppl 15 17 16323824
100. X Li MS Ominsky QT Niu, et al. 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength J Bone Miner Res 23 860 869 18269310 (Pubitemid 351768804)
101. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone; PMID: 20561907
102. MS Ominsky F Vlasseros J Jolette, et al. 2010 Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength J Bone Miner Res 25 5 948 959 1:CAS:528:DC%2BC3cXnt1Kisrg%3D 20200929
103. X Li MS Ominsky KS Warmington S Morony, et al. 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 4 578 588 1:CAS:528:DC%2BD1MXksF2lu7c%3D 19049336
104. NE Lane SL Silverman 2010 Anabolic therapies Curr Osteoporos Rep 8 23 27 20425087
105. VK Yadav JH Ryu N Suda, et al. 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum Cell 135 825 837 1:CAS:528:DC%2BD1cXhsV2jtr%2FP 19041748
106. BD Gelb GP Shi HA Chapman RJ Desnick 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273 1236 1238 1:CAS:528:DyaK28Xltlajsrc%3D 8703060
107. R Kiviranta J Morko H Uusitalo HT Aro E Vuorio J Rantakokko 2001 Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K J Bone Miner Res 16 1444 1452 1:CAS:528:DC%2BD3MXmtVOhtb0%3D 11499867 (Pubitemid 32675196)
108. R Kiviranta J Morko SL Alatalo, et al. 2005 Impaired bone resorption in cathepsin K deficient mice is partially compensated by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio Bone 36 159 172 1:CAS:528:DC%2BD2MXkvVeruw%3D%3D 15664014 (Pubitemid 40128284)
109. J Morko R Kiviranta S Hurme J Rantakokko E Vuorio 2005 Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K Bone 36 854 865 1:CAS:528:DC%2BD2MXjvVOisb0%3D 15826870 (Pubitemid 40616020)
110. J Rantakokko H Uusitalo T Jamsa J Tuukkanen HT Aro E Vuorio 1999 Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model J Bone Miner Res 14 1934 1942 1:CAS:528:DyaK1MXnsFekt70%3D 10571694 (Pubitemid 29521789)
111. G Holzer H Noske T Lang L Holzer U Willinger 2005 Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146 13 17 1:CAS:528:DC%2BD2MXmsVOrtr8%3D 16025086 (Pubitemid 40982014)
112. K Fuller KM Lawrence JL Ross, et al. 2008 Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts Bone 42 200 211 1:CAS:528:DC%2BD2sXhsVOrtrvJ 17962093 (Pubitemid 350302017)
113. JY Gauthier N Chauret W Cromlish, et al. 2008 The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg Med Chem Lett 18 3 923 928 1:CAS:528:DC%2BD1cXhsFWktro%3D 18226527 (Pubitemid 351179363)
114. S Adami J Supronik T Hala, et al. 2006 Effect of one year treatment with the cathepsin-k inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteoporosis/osteopenia J Bone Miner Res 21 S24
115. HG Bone MR McClung C Roux, et al. 2010 Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two year study in postmenopausal women with low bone density J Bone Miner Res 25 5 937 947 19874198
116. SA Stoch S Zajic J Stone, et al. 2009 Effect of cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy ostmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin Pharmacol Ther 86 2 175 182 1:CAS:528:DC%2BD1MXovFOrt7c%3D 19421185
117. AJ Millest SA Breen BE Loveday, et al. 1997 Effects of an inhibitor of cathepsin l on bone resorption in thyroparathyroidectomized and ovariectomized rats Bone 20 465 471 1:CAS:528:DyaK2sXjsV2iu70%3D 9145244 (Pubitemid 27230451)
118. W Potts J Bowyer H Jones, et al. 2004 Cathepsin l deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy Int J Exp Pathol 85 85 96 1:CAS:528:DC%2BD2cXlt1Wqsrc%3D 15154914 (Pubitemid 38703597)
119. JM Delaisse MT Engsig V Everts, et al. 2000 Proteinases in bone resorption: obvious and less obvious roles Clin Chim Acta 291 223 234 1:CAS:528:DC%2BD3cXhtFagurg%3D 10675725 (Pubitemid 30089766)
120. JC Fernandes J Martel-Pelletier JP Pelletier 2002 The role of cytokines in osteoarthritis pathology Biorheology 39 237 246 1:CAS:528: DC%2BD38XmtFWisL4%3D 12082286
121. S Bhasin R Jasuja 2009 Selective androgen receptor modulators as function promoting therapies Curr Opin Clin Nutr Metab Care 12 232 240 1:CAS:528:DC%2BD1MXktl2jsro%3D 19357508
122. W Gao PJ Reiser CC Coss, et al. 2005 Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats Endocrinol 146 4887 4897 1:CAS:528: DC%2BD2MXhtFGqur3O (Pubitemid 41446627)
123. JD Kearbey W Gao R Narayanan, et al. 2007 Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats Pharm Res 24 328 335 1:CAS:528:DC%2BD2sXjtFCqsA%3D%3D 17063395 (Pubitemid 46084804)
124. SA Mousa 2008 Cell adhesion molecules: potential therapeutic and diagnostic implications Mol Biotechnol 38 33 40 1:CAS:528:DC%2BD1cXmtFGisw%3D%3D 18095189 (Pubitemid 351378095)
125. PC Brooks AMP Montgomery M Rosenfield, et al. 1994 Integrin xvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1157 1164 1:CAS:528:DyaK2MXivVWqu7o%3D 7528107
126. 3 integrins "vitronectin receptor" Int J Biochem Cell Biol 29 721 725
127. 3 integrins in osteoclast function J Bone Miner Metab 25 337 344 1:CAS:528:DC%2BD2sXht1aqtLrM 17968485
128. 3, integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women J Clin Endocrinol Metab 90 2022 2028 1:CAS:528:DC%2BD2MXjsFWjt7o%3D 15687321 (Pubitemid 40586234)
129. S Colucci G Mori S Vaira, et al. 2005 l-carnitine and isovaleryl l-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro Calcif Tissue Int 76 458 465 1:CAS:528: DC%2BD2MXms1ylt7Y%3D 15906015 (Pubitemid 41185873)
130. N Patano L Mancini MP Settanni, et al. 2008 l-carnitine fumarate and isovaleryl-l-carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimentally induced osteoporosis in pregnant mice Calcif Tissue Int 82 221 228 1:CAS:528:DC%2BD1cXjsF2gt7g%3D 18265928
131. J Cornish IR Reid 2001 Effects of amylin and adrenomedullin on the skeleton J Musculoskel Neuron Interact 2 15 24 1:CAS:528:DC%2BD3MXms1Sku7c%3D
132. J Cornish KE Callon GJS Cooper IR Reid 1995 Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice Biochem Biophys Res Commun 207 133 139 1:CAS:528:DyaK2MXjsFKhs78%3D 7857256
133. J Cornish KE Callon AR King GJS Cooper IR Reid 1998 Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice Ame J Physiol-Endocrinol Metab 38 E694 E699
134. J Cornish KE Callon DH Coy, et al. 1997 Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo Am J Physiol-Endocrinol Metab 273 E1113 E1120 1:CAS:528:DyaK1cXjvFSmtQ%3D%3D
135. J Cornish KE Callon U Bava, et al. 2001 Systemic administration of adrenomedullin (27-52) increases bone volume and strength in male mice J Endocrinol 170 251 257 1:CAS:528:DC%2BD3MXltlaks7c%3D 11431158 (Pubitemid 32677587)
136. D Naot KE Callon GJS Cooper IR Reid J Cornish 2001 A potential role for adrenomedullin as a local regulator of bone growth Endocrinol 142 1849 1857 1:CAS:528:DC%2BD3MXjt1aktLs%3D (Pubitemid 32405942)
137. LM Montuenga A Martinez MJ Miller EJ Unsworth F Cuttitta 1997 Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action Endocrinol 138 440 451 1:CAS:528:DyaK2sXjsleh (Pubitemid 27009454)
138. J Bronsky R Průsa 2004 Amylin fasting plasma levels are decreased in patients with osteoporosis Osteoporos Int 15 3 243 247 1:STN:280: DC%2BD2c7gs1aqug%3D%3D 14605801 (Pubitemid 38391541)
139. B Uzan A Villemin JM Garel M Cressent 2008 Adrenomodulin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway J Cell Physiol 215 1 122 128 1:CAS:528:DC%2BD1cXjt1Cgs7c%3D 17941085 (Pubitemid 351363197)
140. C Ohlsson BA Bengtsson OG Isaksson TT Andreassen MC Slootweg 1998 Growth hormone and bone Endocr Rev 19 55 79 1:CAS:528:DyaK1cXhtlagtL8%3D 9494780 (Pubitemid 29122074)
141. JP Liu J Baker AS Perkins EJ Robertson A Efstratiadis 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type 1 IGF receptor (IGF1r) Cell 75 59 72 1:CAS:528:DyaK2cXps12nsg%3D%3D 8402901 (Pubitemid 23306021)
142. D Bikle S Majumdar A Laib, et al. 2001 The skeletal structure of insulin-like growth factor I-deficient mice J Bone Miner Res 16 2320 2329 1:CAS:528:DC%2BD38XhtlShtg%3D%3D 11760848 (Pubitemid 33104725)
143. JL Fowlkes KM Thrailkill L Liu, et al. 2006 Effects of systemic and local administration of recombinant human IGF-I (rjIGF-I) on de novo bone formation in an aged mouse model J Bone Miner Res 21 1359 1366 1:CAS:528: DC%2BD28XhtVSrtr3F 16939394 (Pubitemid 44300042)
144. Kanazawa I, Yamaguchi T, Sugimoto T (2010) Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. doi: 10.1007/s00198-010-1310-6 [Epub ahead of print]
145. MW Hamrick PL McNeil SL Patterson 2010 Role of muscle-derived growth factors in bone formation J Musculoskelet Neuronal Interact 10 1 64 70 1:CAS:528:DC%2BC3cXjtVKhtLc%3D 20190381
146. JT Woo M Kawatani M Kato, et al. 2006 Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts Proc Natl Acad Sci USA 103 4729 4734 1:CAS:528:DC%2BD28Xjtl2gtrw%3D 16537392
147. JT Woo T Yonezawa BY Cha T Teruya K Nagai 2008 Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation function and survival J Pharmacol Sci 106 547 554 1:CAS:528:DC%2BD1cXltlCjs74%3D 18431038 (Pubitemid 351556231)
148. H Muguruma S Yano S Kakiuchi, et al. 2005 Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity Clin Cancer Res 11 24 8822 8828 1:CAS:528: DC%2BD2MXhtlWrsbnF 16361571 (Pubitemid 43005934)
149. GA Clines 2010 Prospects for osteoprogenitor stem cells in fracture repair and osteoporosis Curr Opin Organ Transplant 15 73 78 19935065
150. R Quarto M Mastrogiacomo R Cancedda, et al. 2001 Repair of large bone defects with the use of autologous bne marrow stromal cells N Eng J Med 344 385 386 1:STN:280:DC%2BD3M7gtVKitQ%3D%3D (Pubitemid 32107654)
151. EM Horwitz PL Gordon WK Koo, et al. 2002 Isolated allogenic bone marrow derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfect: implications for cell therapy of bone Proc Natl Acad Sci USA 99 8932 8937 1:CAS:528:DC%2BD38XltF2htb8%3D 12084934 (Pubitemid 34693661)
152. Y Tang W Tang Y Lin, et al. 2008 Combination of bone tissue engineering and BMP-2 gene transfection promotes bone healing in osteoporotic rats Cell Biol Int 32 1150 1157 1:CAS:528:DC%2BD1cXhtVens7bM 18638562
153. P Tontonoz E Hu BM Spiegelman 1994 Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 1147 1156 1:STN:280:DyaK2M%2FpsVaqsg%3D%3D 8001151